Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Ovarian Neoplasms × vandetanib × Clear all

Phase

Phase 2 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Medullary 3 Thyroid Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Multiple Endocrine Neoplasia Type 2b 1 Multiple Endocrine Neoplasia Type 2a 1 Multiple Endocrine Neoplasia 1 Gliosarcoma 1 Glioblastoma 1 Carcinoma, Renal Cell 1

Interventions

Carboplatin 44 Paclitaxel 27 pembrolizumab 23 Cyclophosphamide 18 Nivolumab 14 Bevacizumab 13 Topotecan 12 liposomal doxorubicin 10 Filgrastim 10 Cisplatin 10 olaparib 9 Peripheral Blood Stem Cell Transplantation 9 Gemcitabine 9 fludarabine 8 durvalumab 7 aldesleukin 6 Ipilimumab 6 Interleukin-2 6 niraparib 5 epacadostat 5 Ifosfamide 5 Docetaxel 5 poly ICLC 4 pazopanib 4 cemiplimab 4 atezolizumab 4 Temozolomide 4 Specimen Handling 4 Oxaliplatin 4 Fulvestrant 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00862836 2016-10-10

ZACFAST

Sanofi

Phase 1/2 Terminated

15 enrolled 13 charts

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡